Theragenics' sales slide as buyout looms; Kips Bay enrolling FDA-targeted trial;

@FierceMedDev: Alere declares victory in proxy challenge. Article | Follow @FierceMedDev

@DamianFierce: Losses mounting, Invacare sells off another unit for $45M. Story | Follow @DamianFierce

@MichaelGFierce: Luminex axing 5% of workforce as reimbursement dries up. Article | Follow @MichaelGFierce

> Theragenics ($TGX) reported an 8% drop in revenue and another net loss in the second quarter, all as the company waits to be acquired by Juniper for a reported $68 million. Results

> Hologic ($HOLX) has launched a new bone imaging system used to assess osteoporosis, cardiovascular disease and obesity. Release

> Cook Medical has completed enrollment in a study of a new vascular access technique to treat peripheral artery disease. News

> GenMark Diagnostics ($GNMK) snagged $5.2 million in revenue last quarter, a 44% increase, but increased its net loss 42.8% to $8 million. More

> Kips Bay Medical ($KIPS) is enrolling an FDA-targeted trial for its external saphenous vein graft device, designed for use in coronary artery bypass surgeries. Item

> DexCom's ($DXCM) revenue jumped 65% to $35.5 million last quarter, and the diabetes device outfit narrowed its net loss by about 31% to $10.1 million. Financials

Biotech News

@FierceBiotech: Ousted scientist fires back at GSK's high-pressure R&D strategy in China. Story | Follow @FierceBiotech

@JohnCFierce: Is the silly season on biotech IPOs over? No, Intrexon debuts with $2B market value. Item | Follow @JohnCFierce

@RyanMFierce: Biotech M&A gossip: Amgen buyout of Onyx could happen soon. More | Follow @RyanMFierce

@EmilyMFierce: NIH to open genomic data of HeLa cells to researchers. Article | Follow @EmilyMFierce

> GlaxoSmithKline wires up $50M VC fund for bioelectronic treatment effort. Report

> Array slashes staff as Amgen pulls the plug on diabetes drug pact. News

Pharma News

@FiercePharma: Tyson suspends use of Merck growth enhancer for cattle b/c some having difficulty walking. Merck says Zilmax safe. Item | Follow @FiercePharma

@CarlyHFierce: ICYMI: On Vivus' Q2 earnings and plans from new CEO Tony Zook (formerly of AstraZeneca) to increase Qsymia sales. More | Follow @CarlyHFierce

> Sanofi faces bribery allegations from China whistleblower. Story

> Wanted: Buyers for Aptalis Pharma. Must be willing to pay $3B-plus. Article

> Endo invests big in Qualitest to push generic growth. More

Vaccines News

> Flu vaccine tablet developer raises $20M. News

> PharmAthene to add antibody assets in Theraclone merger. Item

> Sanofi advances C. diff vaccine into PhIII. More

> Israel buys 500,000 polio vaccines for immunization push. Article

> GSK adding 2-D barcode to 4-in-1 flu vaccine packaging. Story

> Dana-Farber sees promise in leukemia vaccine trial. More

Pharma Manufacturing News

@EricPFierce: Pharma Tech Industries to expand facility in Missouri. Story | Follow @EricPFierce

> GAO report says FDA needs clear authority over compounders. News

> Ranbaxy gets site for second Malaysian plant. Story

> When it comes to Viagra, counterfeiters just can get enough. Article

> Endo investing $100M in Qualitest manufacturing. More

> Recall expert takes services to Europe. Item

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.